“…The second incidence peak in women after menopause is in line with this suggestion. Indeed, female patients with schizophrenia in the low estrogen phase of their menstrual cycle have more severe symptoms (Grigoriadis and Seeman, 2002), and studies controlling for estrogen plasma levels demonstrate a negative correlation between 17β-estradiol levels and severity of schizophrenia symptoms in women (Gattaz et al, 1994;Riecher-Rössler et al, 1994;Bergemann et al, 2007), as well as in men (Kaneda and Ohmori, 2005). In a previous review article, we performed a meta-analysis of five randomized controlled trials (RCTs) on the efficacy of estrogen augmentation in premenopausal women with schizophrenia and found a significant mean effect on total, positive, and negative symptom severity (Begemann et al, 2012).…”